ASX Stocks: 3 Companies Estimated To Be Trading Below Their Fair Value
As the Australian market prepares for a positive opening, buoyed by strong performances on Wall Street and easing interest rate concerns, investors are keenly observing opportunities that may arise from these favorable conditions. In such an environment, identifying stocks that are estimated to be trading below their fair value can be particularly appealing, as they offer potential for growth amidst broader market optimism.
Top 10 Undervalued Stocks Based On Cash Flows In Australia
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Tasmea (ASX:TEA) | A$9.88 | A$18.26 | 45.9% |
| StepChange Holdings (ASX:STH) | A$0.12 | A$0.24 | 49.1% |
| SciDev (ASX:SDV) | A$0.155 | A$0.3 | 47.7% |
| ReadyTech Holdings (ASX:RDY) | A$1.55 | A$2.84 | 45.5% |
| PolyNovo (ASX:PNV) | A$1.03 | A$1.96 | 47.4% |
| Nuix (ASX:NXL) | A$2.00 | A$3.88 | 48.5% |
| Nickel Industries (ASX:NIC) | A$0.83 | A$1.55 | 46.5% |
| Infotrust (ASX:ITS) | A$0.27 | A$0.53 | 48.7% |
| Catapult Sports (ASX:CAT) | A$3.22 | A$6.10 | 47.2% |
| Bellevue Gold (ASX:BGL) | A$1.70 | A$3.25 | 47.6% |
Here we highlight a subset of our preferred stocks from the screener.
4DMedical (ASX:4DX)
Overview: 4DMedical Limited is a medical technology company operating in the United States and Australia, with a market cap of A$2.16 billion.
Operations: The company's revenue is primarily derived from its Medical Technology R&D of Lung Function Analysis segment, amounting to A$7.06 million.
Estimated Discount To Fair Value: 19.4%
4DMedical's recent earnings report shows a net loss of A$204.44 million, but strategic moves like its partnership with Azra AI and the TGA approval for CT:VQ technology could enhance future cash flows. The stock trades at A$3.6, slightly below its estimated fair value of A$4.47, indicating some undervaluation based on discounted cash flow analysis. Revenue is forecast to grow significantly faster than the Australian market average, potentially improving financial stability over time.
- Insights from our recent growth report point to a promising forecast for 4DMedical's business outlook.
- Dive into the specifics of 4DMedical here with our thorough financial health report.
Magellan Financial Group (ASX:MFG)
Overview: Magellan Financial Group Limited is a publicly owned investment manager with a market cap of A$2.56 billion.
Operations: The company's revenue segments include A$5.02 million from Corporate, A$40.10 million from Partnerships & Investments, and A$205.69 million from Investment Management Services.
Estimated Discount To Fair Value: 44.9%
Magellan Financial Group trades at A$8.74, significantly below its estimated future cash flow value of A$15.85, highlighting undervaluation based on cash flows. Despite a dividend yield of 7.44%, it is not well covered by earnings or free cash flows, and shareholder dilution has occurred recently. Earnings are forecast to grow at 15.38% annually, outpacing the Australian market's average growth rate, while revenue is expected to increase by 20.7% per year.
- The analysis detailed in our Magellan Financial Group growth report hints at robust future financial performance.
- Get an in-depth perspective on Magellan Financial Group's balance sheet by reading our health report here.
Supply Network (ASX:SNL)
Overview: Supply Network Limited supplies aftermarket parts to the commercial vehicle market in Australia and New Zealand, with a market cap of A$1.55 billion.
Operations: The company generates revenue of A$403.09 million from providing aftermarket parts for the commercial vehicle sector in Australia and New Zealand.
Estimated Discount To Fair Value: 27.6%
Supply Network Limited, priced at A$35.49, is trading 27.6% below its estimated cash flow value of A$49, indicating undervaluation based on cash flows. Recent earnings show strong performance with net income rising to A$47.63 million from A$40.02 million the previous year and a dividend increase to 44 cents per share. Revenue growth is projected at 10.1% annually, surpassing the Australian market's average rate of 5.3%.
- Upon reviewing our latest growth report, Supply Network's projected financial performance appears quite optimistic.
- Click to explore a detailed breakdown of our findings in Supply Network's balance sheet health report.
Taking Advantage
- Access the full spectrum of 47 Undervalued ASX Stocks Based On Cash Flows by clicking on this link.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com